Maglalang, P., Gonzalez, D., Muller, W., Hornik, C., Goldstein, S., Rathore, M., … Zimmerman, K. (2025). PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING TO CHARACTERIZE THE DISPOSITION OF TOPIRAMATE IN CHILDREN WITH AND WITHOUT OBESITY USING REAL-WORLD DATA. In CLINICAL PHARMACOLOGY & THERAPEUTICS (Vol. 117, pp. S60–S61).

Maglalang, P., D. Gonzalez, W. Muller, C. Hornik, S. Goldstein, M. Rathore, J. Ford, et al. “PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING TO CHARACTERIZE THE DISPOSITION OF TOPIRAMATE IN CHILDREN WITH AND WITHOUT OBESITY USING REAL-WORLD DATA.” In CLINICAL PHARMACOLOGY & THERAPEUTICS, 117:S60–61, 2025.

Maglalang P, Gonzalez D, Muller W, Hornik C, Goldstein S, Rathore M, et al. PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING TO CHARACTERIZE THE DISPOSITION OF TOPIRAMATE IN CHILDREN WITH AND WITHOUT OBESITY USING REAL-WORLD DATA. In: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2025. p. S60–1.

Maglalang, P., et al. “PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING TO CHARACTERIZE THE DISPOSITION OF TOPIRAMATE IN CHILDREN WITH AND WITHOUT OBESITY USING REAL-WORLD DATA.” CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 117, 2025, pp. S60–61.

Maglalang P, Gonzalez D, Muller W, Hornik C, Goldstein S, Rathore M, Ford J, Balevic S, Sinha J, Edginton A, Chen J, Anand R, Zimmerman K. PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING TO CHARACTERIZE THE DISPOSITION OF TOPIRAMATE IN CHILDREN WITH AND WITHOUT OBESITY USING REAL-WORLD DATA. CLINICAL PHARMACOLOGY & THERAPEUTICS. 2025. p. S60–S61.